NCT01946711

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi

A Pilot Study to Investigate the Efficacy and Safety of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (CRS) With Polyposis Nasi in Adult Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Pari Pharma GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the selected parameter should allow a correlation between an objective methodology and the clinical outcome of the study patients.

Conditions

• Rhinosinusitis
• Chronic Polyposis

Interventions

Type	Name	Description
DRUG	Budesonide	Inhalation
DRUG	Budesonide	Nasal spray

Timeline

• Start date: 2013-08-28
• Primary completion: 2020-02-03
• Completion: 2021-06-21
• First posted: 2013-09-20
• Last updated: 2022-04-12
• Results posted: 2022-04-12

Locations

4 sites across 1 country: Germany